Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

(2015) R.T. Bartus et al.   NEUROBIOLOGY OF DISEASE

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy

(2013) Raymond T Bartus et al.   MOLECULAR THERAPY

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

(2013) Christopher D. Herzog et al.   NEUROBIOLOGY OF DISEASE

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

(2013) R. T. Bartus et al.   NEUROLOGY

 -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons

(2012) M. Decressac et al.   Science Translational Medicine

Open-label surgical trials for Parkinson disease: Time for reconsideration

(2011) Ron L. Alterman et al.   ANNALS OF NEUROLOGY

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

(2011) Raymond T. Bartus et al.   NEUROBIOLOGY OF DISEASE

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains

(2010) Raymond T. Bartus et al.   MOVEMENT DISORDERS

Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys

(2009) Xiaomin Su et al.   HUMAN GENE THERAPY

Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV  -Synucleinopathy

(2009) C. Y. Chung et al.   JOURNAL OF NEUROSCIENCE

Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related Obesity

(2009) Fredric P Manfredsson et al.   MOLECULAR THERAPY

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

(2008) William J Marks et al.   LANCET NEUROLOGY

Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum

(2008) Christopher D Herzog et al.   MOLECULAR THERAPY